Digital Therapeutics
Software that works like medicine. These companies are creating clinically validated digital tools that treat and manage diseases just like traditional pharmaceuticals, but with the scalability of technology. Professional investors see enormous potential in this rapidly evolving healthcare frontier.
About This Group of Stocks
Our Expert Thinking
Digital therapeutics represents the next evolution in healthcare, where FDA-cleared software serves as medicine itself. These companies create evidence-based interventions delivered directly to patients via apps and platforms, transforming treatment for chronic diseases, mental health conditions, and more.
What You Need to Know
This portfolio spans the digital health ecosystem, from specialized software developers to telehealth platforms and supportive technologies. A key catalyst is growing regulatory acceptance and new reimbursement pathways, validating both the clinical effectiveness and commercial potential of these innovations.
Why These Stocks
We've selected companies whose primary business involves creating software-based medical interventions, ensuring direct exposure to this innovative field. Many are seeing increasing insurance coverage decisions, which is critical for widespread adoption and long-term revenue growth.
Why You'll Want to Watch These Stocks
Software is Becoming Medicine
These companies are creating FDA-cleared apps that actually treat diseases—not just track symptoms. It's an entirely new category of medicine with massive growth potential.
Insurance Companies are Paying
A major catalyst is happening right now: insurers are increasingly covering these digital treatments, unlocking billions in potential revenue that wasn't accessible before.
Early Stage with Big Backers
Major pharmaceutical companies and healthcare systems are partnering with these innovators, signaling their belief in the technology's transformative potential.
